Editorial: Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma.
作者信息
Hsu Tsung-I
机构信息
Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei, Taiwan.
International Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
出版信息
Front Oncol. 2023 Jul 14;13:1220063. doi: 10.3389/fonc.2023.1220063. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma.社论：胶质母细胞瘤中获得治疗抗性的代谢重编程
Front Oncol. 2023 Jul 14;13:1220063. doi: 10.3389/fonc.2023.1220063. eCollection 2023.
2
Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation.通过增强脂肪酸氧化中线粒体活性，重新编程花生四烯酸代谢可使胶质母细胞瘤对替莫唑胺产生耐药性。
J Biomed Sci. 2022 Mar 25;29(1):21. doi: 10.1186/s12929-022-00804-3.
3
Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: An Editorial Highlight for 'Transcriptional control of O -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma' on page 780.概述干细胞程序在调节 O6-甲基鸟嘌呤 DNA 甲基转移酶和胶质母细胞瘤替莫唑胺耐药中的作用：“胶质母细胞瘤中 O-甲基鸟嘌呤 DNA 甲基转移酶表达和替莫唑胺耐药的转录控制”的社论要点，第 780 页。
J Neurochem. 2018 Mar;144(6):688-690. doi: 10.1111/jnc.14280.
4
Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma.髓源性抑制细胞的代谢和功能重编程及其在胶质母细胞瘤中的治疗控制
Cell Stress. 2019 Jan 23;3(2):47-65. doi: 10.15698/cst2019.02.176.
5
Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment.替莫唑胺耐药的胶质母细胞瘤治疗的治疗观点。
Cancer Invest. 2021 Sep;39(8):627-644. doi: 10.1080/07357907.2021.1952595. Epub 2021 Jul 19.
6
Antioxidant responses related to temozolomide resistance in glioblastoma.抗氧化反应与脑胶质瘤中替莫唑胺耐药相关。
Neurochem Int. 2021 Oct;149:105136. doi: 10.1016/j.neuint.2021.105136. Epub 2021 Jul 16.
7
JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.JNK通过调节MGMT表达促进胶质母细胞瘤干细胞样细胞对替莫唑胺的耐药性。
Int J Oncol. 2014 Feb;44(2):591-9. doi: 10.3892/ijo.2013.2209. Epub 2013 Dec 5.
8
c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.c-Myc-miR-29c-REV3L 信号通路驱动胶质母细胞瘤对替莫唑胺耐药的获得。
Brain. 2015 Dec;138(Pt 12):3654-72. doi: 10.1093/brain/awv287. Epub 2015 Oct 8.
9
An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?多形性胶质母细胞瘤与替莫唑胺耐药性概述：基于液相色谱-质谱联用的蛋白质组学能否揭示替莫唑胺耐药的根本机制？
Front Oncol. 2023 Apr 26;13:1166207. doi: 10.3389/fonc.2023.1166207. eCollection 2023.
10
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.RSL3 诱导的铁死亡增强替莫唑胺对神经胶质瘤细胞的抑制作用，但与铁蛋白重链 1 和铁蛋白轻链的表达呈负相关。
Lab Invest. 2022 Jul;102(7):741-752. doi: 10.1038/s41374-022-00779-7. Epub 2022 Mar 28.
引用本文的文献
1
Purine metabolism rewiring improves glioblastoma susceptibility to temozolomide treatment.嘌呤代谢重编程可提高胶质母细胞瘤对替莫唑胺治疗的敏感性。
Cell Death Dis. 2025 Apr 24;16(1):336. doi: 10.1038/s41419-025-07667-0.
2
Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance.将胶质母细胞瘤中的代谢重编程作为克服治疗抗性的新策略。
Front Cell Dev Biol. 2025 Feb 26;13:1535073. doi: 10.3389/fcell.2025.1535073. eCollection 2025.
Zotero 插件